Opinion|Videos|July 23, 2024
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Judge Denies Preliminary Injunction in Medicaid Work Requirements Case
2
AHRQ Grant Freeze Halts Patient Safety Research Nationwide
3
Can Oral Semaglutide Reduce Heavy Drinking in Alcohol Use Disorder?
4
Contributor: Artificial Intelligence Grows Across Health Care, Led by Administrative Processes
5